Patent Extension Application from Wenderoth Lind & Ponack LLP (on behalf of AskAt Inc)

Other agency documents in this docket

• FDA-2016-E-2530-0009Letter from FDA CDER to Wenderoth, Lind, & Ponack, L.L.P.
• FDA-2016-E-2530-0008Letter from FDA CDER to U.S. Patent and Trademark Office
• FDA-2016-E-2530-0007Galliprant RRV chal-redacted
• FDA-2016-E-2530-0006Letter from FDA CDER to U.S. Patent and Trademark Office
• FDA-2016-E-2530-0005Determination of Regulatory Review Period for Purposes of Patent Extension; GALLIPRANT
• FDA-2016-E-2530-0004Letter from FDA CDER to U.S. Patent and Trademark Office
• FDA-2016-E-2530-0003Letter from FDA CDER to the U.S. Patent and Trademark Office
• FDA-2016-E-2530-0002Letter from U.S. Patent and Trademark Office